Premium
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)
Author(s) -
Advani Anjali S.,
Gibson Sarah,
Douglas Elizabeth,
Diacovo Julia,
Elson Paul,
Kalaycio Matt,
Copelan Ed,
Sekeres Mikkael,
Sobecks Ronald,
Sungren Shawnda,
Lagoo Anand,
Rizzieri David,
Hsi Eric
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2011.08607.x
Subject(s) - immunohistochemistry , hazard ratio , medicine , confidence interval , acetylation , histone h4 , histone deacetylase , univariate analysis , oncology , multivariate analysis , histone , gastroenterology , biology , genetics , gene
Summary Histone H4 acetylation was examined by immunohistochemistry in patients with acute lymphocytic leukaemia (ALL) in first relapse. Univariate and multivariate models identified correlates of complete remission (CR) and overall survival (OS). No variables were associated with achievement of CR. In multivariate analysis, weak histone H4 acetylation [Hazard Ratio (HR) 2·20, 95% confidence interval (CI) 0·93–5·23, P = 0·07], shorter interval from diagnosis to relapse (<9 vs. 9–24 vs. >24 months) (HR 1·82, 95% CI 1·20–2·75, P = 0·005), and central nervous system involvement (HR 3·43, 95% CI 1·31–8·99, P = 0·01) were independent poor prognostic factors for OS. These data provide a rationale for the use of histone deacetylase inhibitors in the treatment of relapsed ALL.